Related references
Note: Only part of the references are listed.Target Trial Emulation: A Design Tool for Cancer Clinical Trials
Sandi A. Kwee et al.
JCO Clinical Cancer Informatics (2023)
Head-to-head comparison of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in advanced pancreatic cancer: a target trial emulation using real-world data
Devon J. Boyne et al.
ANNALS OF EPIDEMIOLOGY (2023)
Alternative payment models for durable and potentially curative therapies: The case of gene therapy for haemophilia A
Clifford Goodman et al.
HAEMOPHILIA (2022)
Double bad luck: Should rare diseases get special treatment?
Adam Hutchings
JOURNAL OF MEDICAL ETHICS (2022)
Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England
Renske M. T. ten Ham et al.
VALUE IN HEALTH (2022)
Consideration of quality of life in the health technology assessments of rare disease treatments
Elena Nicod et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2022)
Development of a framework and decision tool for the evaluation of health technologies based on surrogate endpoint evidence
Oriana Ciani et al.
HEALTH ECONOMICS (2022)
Design and analysis features used in small population and rare disease trials: A targeted review
Giles Partington et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2022)
A Systematic Review of Health Technology Assessments of Chimeric Antigen Receptor T-Cell Therapies in Young Compared With Older Patients
Amy Gye et al.
VALUE IN HEALTH (2022)
A systematic review of economic evaluations of advanced therapy medicinal products
Huw Lloyd-Williams et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Managing access to advanced therapy medicinal products: Challenges for NHS Wales
Andrew R. Champion et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Variation in market access decisions for cell and gene therapies across the United States, Canada, and Europe
Sean Tunis et al.
HEALTH POLICY (2021)
Health Technology Assessment With Diminishing Returns to Health: The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Approach
Darius N. Lakdawalla et al.
VALUE IN HEALTH (2021)
Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision
Simone A. Huygens et al.
PHARMACOECONOMICS (2021)
Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations
Louis P. Garrison et al.
VALUE IN HEALTH (2021)
Health Technology Assessment of Advanced Therapy Medicinal Products: Comparison Among 3 European Countries
Lucia Gozzo et al.
FRONTIERS IN PHARMACOLOGY (2021)
The use of innovative payment mechanisms for gene therapies in Europe and the USA
Jesper Jorgensen et al.
REGENERATIVE MEDICINE (2021)
Broadening the Concept of Value: A Scoping Review on the Option Value of Medical Technologies
Giulia Fornaro et al.
VALUE IN HEALTH (2021)
Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel
Karen M. Facey et al.
PHARMACOECONOMICS (2021)
Economic Evidence on Potentially Curative Gene Therapy Products: A Systematic Literature Review
Joseph Khoa Ho et al.
PHARMACOECONOMICS (2021)
Considering potential solutions for limitations and challenges in the health economic evaluation of gene therapies
Michal Pochopien et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2021)
The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy
Entela Xoxi et al.
FRONTIERS IN PHARMACOLOGY (2021)
Do Advanced Therapies Have a Future in the Low- and Middle-Income Countries-The Case of Bulgaria, Romania, and Poland
Maria Kamusheva et al.
FRONTIERS IN PUBLIC HEALTH (2021)
Examining the impact of different country processes for appraising rare disease treatments: a case study analysis
Amanda Whittal et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2021)
Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?
Virginia Ronco et al.
JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE (2021)
Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions
Eline van Overbeeke et al.
DRUG DISCOVERY TODAY (2021)
Are supplemental appraisal/reimbursement processes needed for rare disease treatments? An international comparison of country approaches
Elena Nicod et al.
ORPHANET JOURNAL OF RARE DISEASES (2020)
Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies
Aris Angelis et al.
PHARMACOECONOMICS (2020)
A Review of Methodological Considerations for Economic Evaluations of Gene Therapies and Their Application in Literature
Renske M. T. ten Ham et al.
VALUE IN HEALTH (2020)
Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies
Sissel Michelsen et al.
FRONTIERS IN PHARMACOLOGY (2020)
Advanced therapy medicinal products: value judgement and ethical evaluation in health technology assessment
Elisabete Goncalves
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2020)
HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies
Doug Coyle et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2020)
Advances in Methods and Novel Applications for Measuring Family Spillover Effects of Illness
Lisa A. Prosser et al.
PHARMACOECONOMICS (2019)
Value-Based Pricing for Emerging Gene Therapies: The Economic Case for a Higher Cost-Effectiveness Threshold
Louis P. Garrison et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2019)
Future of Patients in Healthcare Evaluation: The Patient-Informed Reference Case
Julia F. Slejko et al.
VALUE IN HEALTH (2019)
Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy
Michael F. Drummond et al.
VALUE IN HEALTH (2019)
New Cost-Effectiveness Methods to Determine Value-Based Prices for Potential Cures: What Are the Options?
Steven D. Pearson et al.
VALUE IN HEALTH (2019)
AN UPDATED TWO-YEAR SURVIVAL ANALYSIS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (R/R-LBCL)
I Diakite et al.
VALUE IN HEALTH (2019)
A Beginner's Guide to Understanding Curative Therapies
Don Husereau et al.
VALUE IN HEALTH (2019)
Are Global Health Systems Ready for Transformative Therapies?
Eric Faulkner et al.
VALUE IN HEALTH (2019)
Unmet Medical Need: An Introduction to Definitions and Stakeholder Perceptions
Rick A. Vreman et al.
VALUE IN HEALTH (2019)
Hurdles in gene therapy regulatory approval: a retrospective analysis of European Marketing Authorization Applications
Marta Carvalho et al.
DRUG DISCOVERY TODAY (2019)
Methods for the analysis of multiple endpoints in small populations: A review
Robin Ristl et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2019)
Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare
Bengt Jonsson et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2019)
Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3]
Darius N. Lakdawalla et al.
VALUE IN HEALTH (2018)
Applicability and added value of novel methods to improve drug development in rare diseases
Marian Mitroiu et al.
ORPHANET JOURNAL OF RARE DISEASES (2018)
Comparing Increments in Utility of Health: An Individual-based Approach
Matthew Taylor et al.
VALUE IN HEALTH (2017)
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Michael Crump et al.
BLOOD (2017)
Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available
Miguel A. Hernan et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2016)
Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework
Oriana Ciani et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
A Comparative Analysis of Two Contrasting European Approaches for Rewarding the Value Added by Drugs for Cancer: England Versus France
Michael Drummond et al.
PHARMACOECONOMICS (2014)